CDNA vs IMDX
CDNA: CareDx is a precision medicine leader providing diagnostic testing, digital health tools, and patient support services to improve outcomes for transplant and oncology patients. IMDX: iMDx is disrupting the transplant diagnostics market by enabling hospitals to run their own donor-derived cell-free DNA (dd-cfDNA) tests in-house through a decentralized kitted model.
Side-by-side fundamentals
| Metric | CDNA | IMDX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $69.20 | $3.03 | |
| Market cap | $3.6B | $99M | |
| P/E as of 2026-10-20 | 33.27 | n/a | |
| Net margin FY2025, SEC XBRL | -5.6% | -1238.5% | CDNA higher |
| Gross margin FY2025, SEC XBRL | n/a | +56.7% | |
| Operating margin FY2025, SEC XBRL | -8.1% | -1260.8% | CDNA higher |
| ROE FY2025, SEC XBRL | -7.0% | n/a | |
| ROA FY2025, SEC XBRL | -5.2% | -195.0% | CDNA higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +13.8% | +115.6% | IMDX higher |
| Revenue CAGR (3y) SEC XBRL | +5.7% | +61.8% | IMDX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.36 | 0.91 | |
| 1-year return as of 2026-10-20 close | +354.7% | -48.6% | CDNA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.